Conference Video: Virtual ISPOR 2021
Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. Did you miss Richard’s presentation?
Meeting on the Med 2021 Conference Panel: “Innovation: Shortening the Path to Commercialization in Advanced Therapies”
Clare Sarvary Fourrier, SVP of Operational Strategy (EU) for Precision for Medicine moderates this panel discussion with industry experts to share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.
Upcoming Conference: Virtual ISPOR 2021
Attending Virtual ISPOR 2021 May 17-20? PRECISIONadvisors and PRECISIONheor will be attending with multiple posters, presentations, and workshops. Three posters and one presentation will have a special focus on Orphan diseases. Stay tuned for valuable insights from our experts that you won’t want to miss!
Conference Download: World EPA Congress
Did you miss PRECISIONadvisor’s Richard Macaulay present “The Future of Reimbursement for Cell & Gene Therapies” at World EPA Congress 2021? Don’t miss great insights about cell & gene therapy reimbursement challenges.
ASGCT 2021 Conference Panel: Considerations for the Clinical Development of Cell & Gene Therapies Part 2 – Gene Therapy
Directly following the cell therapy panel discussion in part 1, Precision experts Phil Cyr, Deb Phippard and David Parker, and Project Pharma’s Tony Khoury joined C-Suite leaders from advanced therapy companies for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 2- Gene Therapy.
ASGCT 2021 Conference Panel: Considerations for the Clinical Development of Cell & Gene Therapies Part 1 – Cell Therapy
Miss ASGCT 2021? Check out this cell therapy panel discussion you won’t want to miss! Precision experts David Parker, Alex Grosvenor and Megan Liles, and Project Farma’s John Khoury join biotech executives on the front lines of development for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 1 – Cell Therapy.
MassBio Member Spotlight: Q&A with Precision Value & Health
Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry and support the patients they serve. In May, MassBio put the spotlight on Precision Value & Health with a Q&A with Precision’s Kelly Wilder.
White Paper: Engaging With Integrated Delivery Networks to Address the Social Determinants of Health
Increasingly, stakeholders across the healthcare continuum are recognizing the importance of social determinants of health (SDOH) on outcomes and quality of life.
In this white paper from Precision’s Maureen Hennessey, we use the results of a 2019 PRECISIONvalue survey and a subsequent 2020 post-onset of COVID-19 survey to evaluate perspectives on SDOH and assess the progress of programs to address SDOH.
Cell and gene therapy: the impact of skills gaps in a fast-growing sector
The growing skills gaps in cell and gene therapy have resulted in a bottleneck preventing potentially revolutionary treatments from reaching the patients who need them. Phil Massey and Daniel Foody of Project Farma, part of the Precision ADVANCE collective, weigh in on the effects of the talent gap, and discuss strategies for closing the gap.
Conference Video: World EPA Congress
Congratulations to PRECISIONadvisor’s Richard Macaulay on presenting “The Future of Innovative Reimbursement for Cell and Gene Therapies” at World EPA Congress 2021.